IgG4-Related Disease: Beyond Glucocorticoids

Mitsuhiro Akiyama, Tsutomu Takeuchi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

IgG4-related disease is a heterogeneous immune-mediated fibroinflammatory condition that can affect every single organ. This disease is more prevalent in the elderly (the mean age of patients is above 60 years) and the prevalence rate is estimated to be over 4.6 per 100,000 population. Before making a diagnosis, the exclusion of malignancies, lymphoma, anti-neutrophil cytoplasmic antibody-associated vasculitis, multicentric Castleman disease, and other mimickers is crucial for appropriate treatment. Broad management guidelines have been published emphasizing the need for prompt treatment and the use of glucocorticoids as first-line drug therapy for induction of remission. However, the toxic effects of glucocorticoids are problematic because IgG4-related disease is more prevalent in patients above 60 years of age, a population with frequent comorbid conditions and polypharmacy. Immunosuppressants (cyclophosphamide, methotrexate, leflunomide, and tacrolimus) and targeted immunomodulators (rituximab, XmAb5871, and abatacept) are appealing to overcome potential toxic effects of glucocorticoids and as emerging glucocorticoid-sparing and/or maintenance treatments. In this review, we provide an overview of our understanding of the pathophysiology of the disease (T follicular helper cells, CD4+ cytotoxic T cells, plasmablasts, and alternatively activated M2 macrophages) and clinical characteristics, and highlight the potential targets for treatment intervention.

Original languageEnglish
Pages (from-to)1-13
Number of pages13
JournalDrugs and Aging
DOIs
Publication statusAccepted/In press - 2018 Mar 15

Fingerprint

Glucocorticoids
Immunoglobulin G
Poisons
leflunomide
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Remission Induction
Polypharmacy
Immunologic Factors
Tacrolimus
Therapeutics
Immunosuppressive Agents
Helper-Inducer T-Lymphocytes
Methotrexate
Cyclophosphamide
Population
Lymphoma
Macrophages
Guidelines
T-Lymphocytes
Drug Therapy

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Pharmacology (medical)

Cite this

IgG4-Related Disease : Beyond Glucocorticoids. / Akiyama, Mitsuhiro; Takeuchi, Tsutomu.

In: Drugs and Aging, 15.03.2018, p. 1-13.

Research output: Contribution to journalArticle

@article{7c466a0db61745609cf70f18f2cad722,
title = "IgG4-Related Disease: Beyond Glucocorticoids",
abstract = "IgG4-related disease is a heterogeneous immune-mediated fibroinflammatory condition that can affect every single organ. This disease is more prevalent in the elderly (the mean age of patients is above 60 years) and the prevalence rate is estimated to be over 4.6 per 100,000 population. Before making a diagnosis, the exclusion of malignancies, lymphoma, anti-neutrophil cytoplasmic antibody-associated vasculitis, multicentric Castleman disease, and other mimickers is crucial for appropriate treatment. Broad management guidelines have been published emphasizing the need for prompt treatment and the use of glucocorticoids as first-line drug therapy for induction of remission. However, the toxic effects of glucocorticoids are problematic because IgG4-related disease is more prevalent in patients above 60 years of age, a population with frequent comorbid conditions and polypharmacy. Immunosuppressants (cyclophosphamide, methotrexate, leflunomide, and tacrolimus) and targeted immunomodulators (rituximab, XmAb5871, and abatacept) are appealing to overcome potential toxic effects of glucocorticoids and as emerging glucocorticoid-sparing and/or maintenance treatments. In this review, we provide an overview of our understanding of the pathophysiology of the disease (T follicular helper cells, CD4+ cytotoxic T cells, plasmablasts, and alternatively activated M2 macrophages) and clinical characteristics, and highlight the potential targets for treatment intervention.",
author = "Mitsuhiro Akiyama and Tsutomu Takeuchi",
year = "2018",
month = "3",
day = "15",
doi = "10.1007/s40266-018-0534-6",
language = "English",
pages = "1--13",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - IgG4-Related Disease

T2 - Beyond Glucocorticoids

AU - Akiyama, Mitsuhiro

AU - Takeuchi, Tsutomu

PY - 2018/3/15

Y1 - 2018/3/15

N2 - IgG4-related disease is a heterogeneous immune-mediated fibroinflammatory condition that can affect every single organ. This disease is more prevalent in the elderly (the mean age of patients is above 60 years) and the prevalence rate is estimated to be over 4.6 per 100,000 population. Before making a diagnosis, the exclusion of malignancies, lymphoma, anti-neutrophil cytoplasmic antibody-associated vasculitis, multicentric Castleman disease, and other mimickers is crucial for appropriate treatment. Broad management guidelines have been published emphasizing the need for prompt treatment and the use of glucocorticoids as first-line drug therapy for induction of remission. However, the toxic effects of glucocorticoids are problematic because IgG4-related disease is more prevalent in patients above 60 years of age, a population with frequent comorbid conditions and polypharmacy. Immunosuppressants (cyclophosphamide, methotrexate, leflunomide, and tacrolimus) and targeted immunomodulators (rituximab, XmAb5871, and abatacept) are appealing to overcome potential toxic effects of glucocorticoids and as emerging glucocorticoid-sparing and/or maintenance treatments. In this review, we provide an overview of our understanding of the pathophysiology of the disease (T follicular helper cells, CD4+ cytotoxic T cells, plasmablasts, and alternatively activated M2 macrophages) and clinical characteristics, and highlight the potential targets for treatment intervention.

AB - IgG4-related disease is a heterogeneous immune-mediated fibroinflammatory condition that can affect every single organ. This disease is more prevalent in the elderly (the mean age of patients is above 60 years) and the prevalence rate is estimated to be over 4.6 per 100,000 population. Before making a diagnosis, the exclusion of malignancies, lymphoma, anti-neutrophil cytoplasmic antibody-associated vasculitis, multicentric Castleman disease, and other mimickers is crucial for appropriate treatment. Broad management guidelines have been published emphasizing the need for prompt treatment and the use of glucocorticoids as first-line drug therapy for induction of remission. However, the toxic effects of glucocorticoids are problematic because IgG4-related disease is more prevalent in patients above 60 years of age, a population with frequent comorbid conditions and polypharmacy. Immunosuppressants (cyclophosphamide, methotrexate, leflunomide, and tacrolimus) and targeted immunomodulators (rituximab, XmAb5871, and abatacept) are appealing to overcome potential toxic effects of glucocorticoids and as emerging glucocorticoid-sparing and/or maintenance treatments. In this review, we provide an overview of our understanding of the pathophysiology of the disease (T follicular helper cells, CD4+ cytotoxic T cells, plasmablasts, and alternatively activated M2 macrophages) and clinical characteristics, and highlight the potential targets for treatment intervention.

UR - http://www.scopus.com/inward/record.url?scp=85044040133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044040133&partnerID=8YFLogxK

U2 - 10.1007/s40266-018-0534-6

DO - 10.1007/s40266-018-0534-6

M3 - Article

C2 - 29546609

AN - SCOPUS:85044040133

SP - 1

EP - 13

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

ER -